Latest news
Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study - HCPLiveHCPLive · Fri, 07 Aug 2026 23:10:36 GMTObesity May Influence Biologic Response in PsO, With Effects Varying by Drug Class - Dermatology TimesDermatology Times · Fri, 07 Aug 2026 13:04:42 GMTImpact of Prior Biologic Exposure on Upadacitinib Efficacy in Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials - CureusCureus · Tue, 28 Jul 2026 23:39:24 GMT